DE10254601A1
(de)
|
2002-11-22 |
2004-06-03 |
Ganymed Pharmaceuticals Ag |
Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
|
DE102008061522A1
(de)
|
2008-12-10 |
2010-06-17 |
Biontech Ag |
Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
|
RU2399667C1
(ru)
*
|
2009-04-10 |
2010-09-20 |
Общество С Ограниченной Ответственностью "Лаборатория Клеточных Технологий" |
Способ получения плюрипотентных клеток
|
EP2281579A1
(en)
|
2009-08-05 |
2011-02-09 |
BioNTech AG |
Vaccine composition comprising 5'-Cap modified RNA
|
WO2012006378A1
(en)
|
2010-07-06 |
2012-01-12 |
Novartis Ag |
Liposomes with lipids having an advantageous pka- value for rna delivery
|
HUE047796T2
(hu)
|
2010-07-06 |
2020-05-28 |
Glaxosmithkline Biologicals Sa |
RNS bevitele több immunútvonal bekapcsolására
|
CA2804492A1
(en)
|
2010-07-06 |
2012-01-12 |
Novartis Ag |
Immunisation of large mammals with low doses of rna
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
PT4066856T
(pt)
|
2010-08-31 |
2023-01-02 |
Glaxosmithkline Biologicals Sa |
Lipossomas peguilados para entrega de arn codificador de imunogénio
|
CN103429606A
(zh)
|
2010-10-01 |
2013-12-04 |
现代治疗公司 |
设计核酸及其使用方法
|
CN103269713B
(zh)
|
2010-10-11 |
2016-01-20 |
诺华有限公司 |
抗原递送平台
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
ES2946072T3
(es)
|
2011-05-24 |
2023-07-12 |
BioNTech SE |
Vacunas individualizadas para el cáncer
|
JP2014522842A
(ja)
|
2011-07-06 |
2014-09-08 |
ノバルティス アーゲー |
免疫原性組み合わせ組成物およびその使用
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
RS62993B1
(sr)
|
2011-10-03 |
2022-03-31 |
Modernatx Inc |
Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe
|
SG10201604896TA
(en)
|
2011-12-16 |
2016-08-30 |
Moderna Therapeutics Inc |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
WO2013120500A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
|
WO2013120499A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
|
EP3178488B1
(en)
|
2012-02-15 |
2019-05-01 |
CureVac AG |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
|
WO2013120498A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
|
EP3404103B1
(en)
|
2012-02-15 |
2021-03-24 |
CureVac AG |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
|
EP2814962B1
(en)
|
2012-02-15 |
2018-07-04 |
CureVac AG |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
JP2015513913A
(ja)
|
2012-04-02 |
2015-05-18 |
モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. |
修飾ポリヌクレオチド
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
WO2013151666A2
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of biologics and proteins associated with human disease
|
WO2014028429A2
(en)
|
2012-08-14 |
2014-02-20 |
Moderna Therapeutics, Inc. |
Enzymes and polymerases for the synthesis of rna
|
UA128182C2
(uk)
|
2012-11-13 |
2024-05-01 |
Біонтех Аґ |
Агенти для лікування експресуючих клаудин ракових захворювань
|
EP2920209B1
(en)
|
2012-11-13 |
2020-08-05 |
BioNTech SE |
Agents for treatment of claudin expressing cancer diseases
|
HRP20220607T1
(hr)
|
2012-11-26 |
2022-06-24 |
Modernatx, Inc. |
Terminalno modificirana rna
|
CA2892391C
(en)
|
2012-11-28 |
2023-10-17 |
Biontech Rna Pharmaceuticals Gmbh |
Individualized vaccines for cancer
|
JP2016504050A
(ja)
|
2013-01-17 |
2016-02-12 |
モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. |
細胞表現型の改変のためのシグナルセンサーポリヌクレオチド
|
WO2014159813A1
(en)
|
2013-03-13 |
2014-10-02 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
EP3019619B1
(en)
|
2013-07-11 |
2021-08-25 |
ModernaTX, Inc. |
Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
|
EP3041934A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
CA2926218A1
(en)
|
2013-10-03 |
2015-04-09 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
CN106061466A
(zh)
|
2013-12-19 |
2016-10-26 |
诺华股份有限公司 |
瘦蛋白mRNA组合物和制剂
|
HUE057800T2
(hu)
|
2014-04-23 |
2022-06-28 |
Modernatx Inc |
Nukleinsav vakcinák
|
WO2016005004A1
(en)
*
|
2014-07-11 |
2016-01-14 |
Biontech Rna Pharmaceuticals Gmbh |
Stabilization of poly(a) sequence encoding dna sequences
|
EP4159741A1
(en)
|
2014-07-16 |
2023-04-05 |
ModernaTX, Inc. |
Method for producing a chimeric polynucleotide encoding a polypeptide having a triazole-containing internucleotide linkage
|
WO2016057850A1
(en)
|
2014-10-09 |
2016-04-14 |
Seattle Children' S Hospital (Dba Seattle Children' S Research Institute) |
Long poly (a) plasmids and methods for introduction of long poly (a) sequences into the plasmid
|
DE202015010000U1
(de)
*
|
2014-12-12 |
2023-07-03 |
CureVac SE |
Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression
|
ES2837100T3
(es)
|
2015-08-10 |
2021-06-29 |
Curevac Real Estate Gmbh |
Método de aumento de la replicación de una molécula de ADN circular
|
EP3359670B2
(en)
|
2015-10-05 |
2024-02-14 |
ModernaTX, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
WO2017059902A1
(en)
*
|
2015-10-07 |
2017-04-13 |
Biontech Rna Pharmaceuticals Gmbh |
3' utr sequences for stabilization of rna
|
WO2017066797A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Trinucleotide mrna cap analogs
|
US20190218546A1
(en)
|
2015-10-16 |
2019-07-18 |
Modernatx, Inc. |
Mrna cap analogs with modified phosphate linkage
|
US20190225644A1
(en)
*
|
2015-10-16 |
2019-07-25 |
Modernatx, Inc. |
Mrna cap analogs and methods of mrna capping
|
EP3394093B1
(en)
|
2015-12-23 |
2022-01-26 |
Modernatx, Inc. |
Methods of using ox40 ligand encoding polynucleotides
|
MA43587A
(fr)
|
2016-01-10 |
2018-11-14 |
Modernatx Inc |
Arnm thérapeutiques codant pour des anticorps anti-ctla-4
|
EP3405579A1
(en)
|
2016-01-22 |
2018-11-28 |
Modernatx, Inc. |
Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
|
US11446398B2
(en)
|
2016-04-11 |
2022-09-20 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
EP3442590A2
(en)
|
2016-04-13 |
2019-02-20 |
Modernatx, Inc. |
Lipid compositions and their uses for intratumoral polynucleotide delivery
|
US20190343942A1
(en)
|
2016-04-22 |
2019-11-14 |
Curevac Ag |
Rna encoding a tumor antigen
|
SI3445850T1
(sl)
|
2016-04-22 |
2021-12-31 |
BioNTech SE |
Postopki za zagotavljanje enoverižne RNA
|
WO2017191274A2
(en)
|
2016-05-04 |
2017-11-09 |
Curevac Ag |
Rna encoding a therapeutic protein
|
ES2973443T3
(es)
|
2016-05-18 |
2024-06-20 |
Modernatx Inc |
Polinucleótidos que codifican galactosa-1-fosfato uridililtransferasa para el tratamiento de galactosemia de tipo 1
|
CN109476718B
(zh)
|
2016-05-18 |
2023-07-04 |
莫得纳特斯公司 |
编码免疫调节多肽的mrna的组合及其用途
|
EP4186518A1
(en)
|
2016-05-18 |
2023-05-31 |
ModernaTX, Inc. |
Polynucleotides encoding interleukin-12 (il12) and uses thereof
|
WO2017201346A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
|
MA45052A
(fr)
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
|
EP3458590B9
(en)
|
2016-05-18 |
2021-08-18 |
ModernaTX, Inc. |
Polynucleotides encoding -galactosidase a for the treatment of fabry disease
|
US20190298657A1
(en)
|
2016-05-18 |
2019-10-03 |
Modernatx, Inc. |
Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
|
WO2017201349A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding citrin for the treatment of citrullinemia type 2
|
EP3481430A4
(en)
|
2016-07-11 |
2020-04-01 |
Translate Bio Ma, Inc. |
NUCLEIC ACID CONJUGATES AND USES THEREOF
|
WO2018081788A1
(en)
|
2016-10-31 |
2018-05-03 |
Cornell University |
Methods of enhancing translation ability and stability of rna molecules, treatments, and kits
|
AU2018270111B2
(en)
|
2017-05-18 |
2022-07-14 |
Modernatx, Inc. |
Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
|
US11485972B2
(en)
|
2017-05-18 |
2022-11-01 |
Modernatx, Inc. |
Modified messenger RNA comprising functional RNA elements
|
US20200131498A1
(en)
|
2017-06-14 |
2020-04-30 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase
|
WO2018232006A1
(en)
|
2017-06-14 |
2018-12-20 |
Modernatx, Inc. |
Polynucleotides encoding coagulation factor viii
|
EP3668522A4
(en)
|
2017-08-18 |
2021-04-21 |
Modernatx, Inc. |
EFFECTIVE RNA-BASED VACCINES
|
WO2019104160A2
(en)
|
2017-11-22 |
2019-05-31 |
Modernatx, Inc. |
Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
|
JP7424976B2
(ja)
|
2017-11-22 |
2024-01-30 |
モダーナティエックス・インコーポレイテッド |
プロピオン酸血症の治療用のプロピオニルCoAカルボキシラーゼアルファ及びベータサブユニットをコードするポリヌクレオチド
|
WO2019104152A1
(en)
|
2017-11-22 |
2019-05-31 |
Modernatx, Inc. |
Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
|
SG11202005060YA
(en)
|
2017-12-15 |
2020-06-29 |
Flagship Pioneering Innovations Vi Llc |
Compositions comprising circular polyribonucleotides and uses thereof
|
US11802146B2
(en)
|
2018-01-05 |
2023-10-31 |
Modernatx, Inc. |
Polynucleotides encoding anti-chikungunya virus antibodies
|
MA54676A
(fr)
|
2018-01-29 |
2021-11-17 |
Modernatx Inc |
Vaccins à base d'arn contre le vrs
|
KR20200143391A
(ko)
|
2018-03-15 |
2020-12-23 |
비온테크 알엔에이 파마슈티컬스 게엠베하 |
5'-캡-트리뉴클레오티드- 또는 고차의 올리고뉴클레오티드 화합물 및 이들의 rna 안정화, 단백질 발현 및 치료에서의 사용
|
WO2019200171A1
(en)
|
2018-04-11 |
2019-10-17 |
Modernatx, Inc. |
Messenger rna comprising functional rna elements
|
WO2019241315A1
(en)
|
2018-06-12 |
2019-12-19 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
WO2020023390A1
(en)
|
2018-07-25 |
2020-01-30 |
Modernatx, Inc. |
Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
|
US20220110966A1
(en)
|
2018-09-02 |
2022-04-14 |
Modernatx, Inc. |
Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency
|
MA53608A
(fr)
|
2018-09-13 |
2021-07-21 |
Modernatx Inc |
Polynucléotides codant pour les sous-unités e1-alpha, e1-beta et e2 du complexe alpha-cétoacide déshydrogénase à chaîne ramifiée pour le traitement de la leucinose
|
AU2019337637A1
(en)
|
2018-09-13 |
2021-04-22 |
Modernatx, Inc. |
Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease
|
EP3850102A1
(en)
|
2018-09-14 |
2021-07-21 |
ModernaTX, Inc. |
Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
|
EP3849589A1
(en)
|
2018-09-14 |
2021-07-21 |
ModernaTX, Inc. |
Methods and compositions for treating cancer using mrna therapeutics
|
WO2020069169A1
(en)
|
2018-09-27 |
2020-04-02 |
Modernatx, Inc. |
Polynucleotides encoding arginase 1 for the treatment of arginase deficiency
|
US20210386788A1
(en)
|
2018-10-24 |
2021-12-16 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
MA54503A
(fr)
|
2018-12-19 |
2021-10-27 |
Versameb Ag |
Arn codant pour une protéine
|
AU2020208193A1
(en)
|
2019-01-14 |
2021-07-29 |
BioNTech SE |
Methods of treating cancer with a PD-1 axis binding antagonist and an RNA vaccine
|
US20220142896A1
(en)
|
2019-03-01 |
2022-05-12 |
Flagship Pioneering Innovations Vi, Llc |
Polyribonucleotides and cosmetic uses thereof
|
MA55082A
(fr)
|
2019-03-01 |
2022-01-05 |
Flagship Pioneering Innovations Vi Llc |
Compositions, procédés, et kits pour l'administration de polyribonucléotides
|
WO2020227510A1
(en)
|
2019-05-07 |
2020-11-12 |
Modernatx, Inc. |
Polynucleotides for disrupting immune cell activity and methods of use thereof
|
WO2020227537A1
(en)
|
2019-05-07 |
2020-11-12 |
Modernatx, Inc |
Differentially expressed immune cell micrornas for regulation of protein expression
|
AR118859A1
(es)
*
|
2019-05-08 |
2021-11-03 |
Neon Therapeutics Inc |
Composiciones y métodos de fabricación de células t
|
JP2022532078A
(ja)
|
2019-05-08 |
2022-07-13 |
アストラゼネカ アクチボラグ |
皮膚及び創傷のための組成物並びにその使用の方法
|
EP3987027A1
(en)
|
2019-06-24 |
2022-04-27 |
ModernaTX, Inc. |
Endonuclease-resistant messenger rna and uses thereof
|
EP3986480A1
(en)
|
2019-06-24 |
2022-04-27 |
ModernaTX, Inc. |
Messenger rna comprising functional rna elements and uses thereof
|
WO2021008708A1
(en)
|
2019-07-18 |
2021-01-21 |
Biontech Rna Pharmaceuticals Gmbh |
Method for determining at least one parameter of a sample composition comprising nucleic acid, such as rna, and optionally particles
|
CA3158013A1
(en)
|
2019-10-15 |
2021-04-22 |
Modernatx, Inc. |
Mrnas encoding granulocyte-macrophage colony stimulating factor for treating parkinson's disease
|
EP4096710A1
(en)
|
2020-01-28 |
2022-12-07 |
ModernaTX, Inc. |
Coronavirus rna vaccines
|
WO2021155175A1
(en)
|
2020-01-29 |
2021-08-05 |
Flagship Pioneering Innovations Vi, Llc |
Compositions for translation and methods of use thereof
|
EP4096708A1
(en)
|
2020-01-31 |
2022-12-07 |
Genentech, Inc. |
Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine
|
US20240277830A1
(en)
|
2020-02-04 |
2024-08-22 |
CureVac SE |
Coronavirus vaccine
|
CA3170150A1
(en)
|
2020-02-07 |
2021-08-12 |
Modernatx, Inc. |
Sars-cov-2 mrna domain vaccines
|
EP4103228A1
(en)
|
2020-02-13 |
2022-12-21 |
Institut Pasteur |
Nucleic acid vaccine against the sars-cov-2 coronavirus
|
JP2021185136A
(ja)
|
2020-04-22 |
2021-12-09 |
ビオエンテッヒ・アールエヌエイ・ファーマシューティカルズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
コロナウイルスワクチン
|
WO2021222304A1
(en)
|
2020-04-27 |
2021-11-04 |
Modernatx, Inc. |
Sars-cov-2 rna vaccines
|
JP2023526059A
(ja)
|
2020-05-14 |
2023-06-20 |
モダーナティエックス・インコーポレイテッド |
mRNA治療薬及びエフェクター分子を含むLNP組成物
|
WO2021159130A2
(en)
|
2020-05-15 |
2021-08-12 |
Modernatx, Inc. |
Coronavirus rna vaccines and methods of use
|
US20230233475A1
(en)
|
2020-06-01 |
2023-07-27 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
|
EP4158005A1
(en)
|
2020-06-01 |
2023-04-05 |
ModernaTX, Inc. |
Phenylalanine hydroxylase variants and uses thereof
|
EP4168556A2
(en)
|
2020-06-23 |
2023-04-26 |
ModernaTX, Inc. |
Lnp compositions comprising mrna therapeutics with extended half-life
|
CN111893128A
(zh)
*
|
2020-06-24 |
2020-11-06 |
苏州市泽悦生物技术有限公司 |
利用原核转录系统制备重组真核mRNA的方法及其应用
|
WO2022016125A1
(en)
|
2020-07-17 |
2022-01-20 |
Genentech, Inc. |
Attention-based neural network to predict peptide binding, presentation, and immunogenicity
|
EP4210864A2
(en)
|
2020-09-08 |
2023-07-19 |
Genentech, Inc. |
Systems and methods for producing pharmaceutical compositions using peristaltic pumps and dampeners
|
EP4217371A1
(en)
|
2020-09-25 |
2023-08-02 |
ModernaTX, Inc. |
Multi-proline-substituted coronavirus spike protein vaccines
|
EP4203997A1
(en)
|
2020-10-26 |
2023-07-05 |
Pécsi Tudományegyetem |
Vaccine platform
|
EP4243776A1
(en)
|
2020-11-13 |
2023-09-20 |
Modernatx, Inc. |
Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
|
WO2022101486A1
(en)
|
2020-11-16 |
2022-05-19 |
BioNTech SE |
Pharmaceutical compositions comprising particles and mrna and methods for preparing and storing the same
|
CA3198742A1
(en)
|
2020-11-16 |
2022-05-19 |
Steffen Panzner |
Lnp compositions comprising rna and methods for preparing, storing and using the same
|
WO2022218503A1
(en)
|
2021-04-12 |
2022-10-20 |
BioNTech SE |
Lnp compositions comprising rna and methods for preparing, storing and using the same
|
WO2022106860A1
(en)
|
2020-11-20 |
2022-05-27 |
Pécsi Tudományegyetem |
Recombinant peptides for use in therapy
|
WO2022115645A1
(en)
|
2020-11-25 |
2022-06-02 |
Akagera Medicines, Inc. |
Lipid nanoparticles for delivery of nucleic acids, and related methods of use
|
AU2021405281A1
(en)
|
2020-12-22 |
2023-07-06 |
CureVac SE |
Rna vaccine against sars-cov-2 variants
|
US20230000970A1
(en)
|
2021-01-11 |
2023-01-05 |
Modernatx, Inc. |
Seasonal rna influenza virus vaccines
|
WO2022155530A1
(en)
|
2021-01-15 |
2022-07-21 |
Modernatx, Inc. |
Variant strain-based coronavirus vaccines
|
WO2022155524A1
(en)
|
2021-01-15 |
2022-07-21 |
Modernatx, Inc. |
Variant strain-based coronavirus vaccines
|
US20240102065A1
(en)
|
2021-01-27 |
2024-03-28 |
CureVac SE |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
AU2022220328A1
(en)
|
2021-02-12 |
2023-08-17 |
Modernatx, Inc. |
Lnp compositions comprising payloads for in vivo therapy
|
AU2022237382A1
(en)
|
2021-03-15 |
2023-09-28 |
Modernatx, Inc. |
Therapeutic use of sars-cov-2 mrna domain vaccines
|
JP2024512026A
(ja)
|
2021-03-24 |
2024-03-18 |
モデルナティエックス インコーポレイテッド |
オルニチントランスカルバミラーゼ欠損症の治療を目的とした脂質ナノ粒子及びオルニチントランスカルバミラーゼをコードするポリヌクレオチド
|
US20240226025A1
(en)
|
2021-03-24 |
2024-07-11 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
|
WO2022204390A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
|
WO2022204371A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
|
WO2022204380A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
|
WO2022212711A2
(en)
|
2021-04-01 |
2022-10-06 |
Modernatx, Inc. |
Methods for identification and ratio determination of rna species in multivalent rna compositions
|
AU2022256732A1
(en)
|
2021-04-12 |
2023-10-19 |
Biontech Delivery Technologies Gmbh |
Rna compositions comprising a buffer substance and methods for preparing, storing and using the same
|
WO2022221335A1
(en)
|
2021-04-13 |
2022-10-20 |
Modernatx, Inc. |
Respiratory virus combination vaccines
|
JP2024513999A
(ja)
|
2021-04-14 |
2024-03-27 |
モデルナティエックス インコーポレイテッド |
インフルエンザ-コロナウイルス組み合わせワクチン
|
KR20240006575A
(ko)
|
2021-04-26 |
2024-01-15 |
앵스띠뛰 파스퇴르 |
SARS-CoV-2에 대한 사람 중화 모노클로날 항체 및 이의 용도
|
AU2022271249A1
(en)
|
2021-05-04 |
2023-11-16 |
BioNTech SE |
Immunogen selection
|
WO2022245888A1
(en)
|
2021-05-19 |
2022-11-24 |
Modernatx, Inc. |
Seasonal flu rna vaccines and methods of use
|
WO2022246020A1
(en)
|
2021-05-19 |
2022-11-24 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
|
WO2022266083A2
(en)
|
2021-06-15 |
2022-12-22 |
Modernatx, Inc. |
Engineered polynucleotides for cell-type or microenvironment-specific expression
|
US20240218353A1
(en)
|
2021-06-17 |
2024-07-04 |
Modernatx, Inc. |
Alternative rna purification strategies
|
WO2022271776A1
(en)
|
2021-06-22 |
2022-12-29 |
Modernatx, Inc. |
Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
|
WO2023287751A1
(en)
|
2021-07-12 |
2023-01-19 |
Modernatx, Inc. |
Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia
|
WO2023009499A1
(en)
|
2021-07-27 |
2023-02-02 |
Modernatx, Inc. |
Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease type 1a (gsd1a)
|
AU2022317263A1
(en)
|
2021-07-29 |
2024-01-04 |
BioNTech SE |
Compositions and methods for treatment of melanoma
|
EP4384613A1
(en)
|
2021-08-13 |
2024-06-19 |
ModernaTX, Inc. |
Multicolumn chromatography mrna purification
|
CN115216483B
(zh)
*
|
2021-08-30 |
2024-01-23 |
中国科学院遗传与发育生物学研究所 |
poly(A)尾巴非A修饰在促进mRNA翻译中的应用
|
WO2023030635A1
(en)
|
2021-09-02 |
2023-03-09 |
BioNTech SE |
Potency assay for therapeutic potential of coding nucleic acid
|
WO2023036960A1
(en)
|
2021-09-10 |
2023-03-16 |
BioNTech SE |
Lipid-based rna formulations suitable for therapy
|
WO2023051926A1
(en)
|
2021-09-30 |
2023-04-06 |
BioNTech SE |
Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
|
EP4408871A1
(en)
|
2021-10-01 |
2024-08-07 |
ModernaTX, Inc. |
Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
|
WO2023064469A1
(en)
|
2021-10-13 |
2023-04-20 |
Modernatx, Inc. |
Compositions of mrna-encoded il15 fusion proteins and methods of use thereof
|
EP4186528A1
(en)
|
2021-11-30 |
2023-05-31 |
BioNTech SE |
Oligosaccharide complexes and uses
|
EP4169580A1
(en)
|
2021-10-22 |
2023-04-26 |
BioNTech SE |
Oligosaccharide compounds and complexes
|
WO2023069498A1
(en)
|
2021-10-22 |
2023-04-27 |
Senda Biosciences, Inc. |
Mrna vaccine composition
|
EP4285933A1
(en)
|
2022-05-30 |
2023-12-06 |
BioNTech SE |
Oligosaccharide complexes and uses
|
EP4169579A1
(en)
|
2021-10-22 |
2023-04-26 |
BioNTech SE |
Disulfide oligosaccharide compounds and complexes
|
EP4286394A1
(en)
|
2022-05-30 |
2023-12-06 |
BioNTech SE |
Oligosaccharide compounds and complexes
|
WO2023067121A1
(en)
|
2021-10-22 |
2023-04-27 |
BioNTech SE |
Oligosaccharide compounds and complexes
|
EP4401788A1
(en)
|
2021-10-22 |
2024-07-24 |
BioNTech SE |
Oligosaccharide complexes and uses
|
EP4286004A1
(en)
|
2022-05-30 |
2023-12-06 |
BioNTech SE |
Disulfide oligosaccharide compounds and complexes
|
WO2023067124A1
(en)
|
2021-10-22 |
2023-04-27 |
BioNTech SE |
Disulfide oligosaccharide compounds and complexes
|
EP4238577A3
(en)
|
2021-10-22 |
2023-12-06 |
BioNTech SE |
Compositions for administration of different doses of rna
|
EP4286003A1
(en)
|
2022-05-30 |
2023-12-06 |
BioNTech SE |
Oligosaccharide compounds and complexes
|
EP4169534A1
(en)
|
2021-10-22 |
2023-04-26 |
BioNTech SE |
Oligosaccharide complexes and uses
|
EP4285932A1
(en)
|
2022-05-30 |
2023-12-06 |
BioNTech SE |
Oligosaccharide complexes and uses
|
EP4401789A1
(en)
|
2021-10-22 |
2024-07-24 |
BioNTech SE |
Oligosaccharide complexes and uses
|
WO2023067126A1
(en)
|
2021-10-22 |
2023-04-27 |
BioNTech SE |
Oligosaccharide compounds and complexes
|
EP4169578A1
(en)
|
2021-10-22 |
2023-04-26 |
BioNTech SE |
Oligosaccharide compounds and complexes
|
WO2023073190A1
(en)
|
2021-10-28 |
2023-05-04 |
BioNTech SE |
Rna constructs and uses thereof
|
WO2023076658A1
(en)
|
2021-11-01 |
2023-05-04 |
Modernatx, Inc. |
Mass spectrometry of mrna
|
WO2023077170A1
(en)
|
2021-11-01 |
2023-05-04 |
Modernatx, Inc. |
Polynucleotides encoding integrin beta-6 and methods of use thereof
|
WO2023081311A1
(en)
|
2021-11-05 |
2023-05-11 |
Modernatx, Inc. |
Methods of purifying dna for gene synthesis
|
WO2023083434A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection
|
WO2023092069A1
(en)
|
2021-11-18 |
2023-05-25 |
Modernatx, Inc. |
Sars-cov-2 mrna domain vaccines and methods of use
|
CN118488834A
(zh)
|
2021-11-23 |
2024-08-13 |
赛欧生物医药股份有限公司 |
细菌源性脂质组合物和其用途
|
WO2023107999A2
(en)
|
2021-12-08 |
2023-06-15 |
Modernatx, Inc. |
Herpes simplex virus mrna vaccines
|
WO2023122080A1
(en)
|
2021-12-20 |
2023-06-29 |
Senda Biosciences, Inc. |
Compositions comprising mrna and lipid reconstructed plant messenger packs
|
WO2023126053A1
(en)
|
2021-12-28 |
2023-07-06 |
BioNTech SE |
Lipid-based formulations for administration of rna
|
WO2023132885A1
(en)
|
2022-01-04 |
2023-07-13 |
Modernatx, Inc. |
Methods of purifying dna for gene synthesis
|
WO2023137149A1
(en)
|
2022-01-14 |
2023-07-20 |
Modernatx, Inc. |
In vitro transcription dna purification and recycling
|
WO2023141501A2
(en)
*
|
2022-01-19 |
2023-07-27 |
Virginia Tech Intellectual Properties, Inc. |
Nudix overexpressing engineered plants and uses thereof
|
AU2023215613A1
(en)
|
2022-02-02 |
2024-08-08 |
BioNTech SE |
Agents and methods for targeted delivery to cells
|
WO2023148277A1
(en)
|
2022-02-02 |
2023-08-10 |
BioNTech SE |
Agents and methods for targeted delivery of nucleic acids to cells
|
WO2023150256A1
(en)
|
2022-02-03 |
2023-08-10 |
Modernatx, Inc. |
Continuous precipitation for mrna purification
|
WO2023159197A1
(en)
|
2022-02-18 |
2023-08-24 |
Modernatx, Inc. |
Mrnas encoding checkpoint cancer vaccines and uses thereof
|
WO2023165681A1
(en)
|
2022-03-01 |
2023-09-07 |
BioNTech SE |
Rna lipid nanoparticles (lnps) comprising a polyoxazoline and/or polyoxazine polymer
|
WO2023183909A2
(en)
|
2022-03-25 |
2023-09-28 |
Modernatx, Inc. |
Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
|
WO2023193892A1
(en)
|
2022-04-05 |
2023-10-12 |
BioNTech SE |
Nucleic acid compositions comprising an inorganic polyphosphate and methods for preparing, storing and using the same
|
WO2023196399A1
(en)
|
2022-04-06 |
2023-10-12 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding argininosuccinate lyase for the treatment of argininosuccinic aciduria
|
WO2023196914A1
(en)
|
2022-04-08 |
2023-10-12 |
Modernatx, Inc. |
Influenza nucleic acid compositions and uses thereof
|
WO2023201296A1
(en)
|
2022-04-15 |
2023-10-19 |
Modernatx, Inc. |
Ribosomal engagement potency assay
|
WO2023215498A2
(en)
|
2022-05-05 |
2023-11-09 |
Modernatx, Inc. |
Compositions and methods for cd28 antagonism
|
WO2023230481A1
(en)
|
2022-05-24 |
2023-11-30 |
Modernatx, Inc. |
Orthopoxvirus vaccines
|
WO2023230587A2
(en)
|
2022-05-25 |
2023-11-30 |
Akagera Medicines, Inc. |
Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
|
WO2023232747A1
(en)
|
2022-05-30 |
2023-12-07 |
BioNTech SE |
Complexes for delivery of nucleic acids
|
WO2023237726A1
(en)
|
2022-06-10 |
2023-12-14 |
Pantarhei Oncology B.V. |
An intracellular tumor-specific variant of human zona pellucida glycoprotein 3 and nucleic acids coding therefor for use in the treatment of cancer
|
WO2024002985A1
(en)
|
2022-06-26 |
2024-01-04 |
BioNTech SE |
Coronavirus vaccine
|
WO2024010993A1
(en)
|
2022-07-06 |
2024-01-11 |
Modernatx, Inc. |
Primer design for cell-free dna production
|
WO2024015890A1
(en)
|
2022-07-13 |
2024-01-18 |
Modernatx, Inc. |
Norovirus mrna vaccines
|
WO2024028325A1
(en)
|
2022-08-01 |
2024-02-08 |
BioNTech SE |
Nucleic acid compositions comprising amphiphilic oligo ethylene glycol (oeg)-conjugated compounds and methods of using such compounds and compositions
|
WO2024027910A1
(en)
|
2022-08-03 |
2024-02-08 |
BioNTech SE |
Rna for preventing or treating tuberculosis
|
WO2024028445A1
(en)
|
2022-08-03 |
2024-02-08 |
BioNTech SE |
Rna for preventing or treating tuberculosis
|
WO2024050483A1
(en)
|
2022-08-31 |
2024-03-07 |
Modernatx, Inc. |
Variant strain-based coronavirus vaccines and uses thereof
|
WO2024063788A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
WO2024068674A1
(en)
|
2022-09-26 |
2024-04-04 |
BioNTech SE |
Nucleic acid complexes and uses thereof
|
WO2024084462A1
(en)
|
2022-10-21 |
2024-04-25 |
BioNTech SE |
Nucleic acid complexes and uses thereof
|
WO2024097874A1
(en)
|
2022-11-03 |
2024-05-10 |
Modernatx, Inc. |
Chemical stability of mrna
|
WO2024102434A1
(en)
|
2022-11-10 |
2024-05-16 |
Senda Biosciences, Inc. |
Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
|
WO2024107754A1
(en)
|
2022-11-15 |
2024-05-23 |
Genentech, Inc. |
Selection of diverse candidate peptides for peptide therapeutics
|
WO2024130158A1
(en)
|
2022-12-16 |
2024-06-20 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
|
WO2024137589A2
(en)
|
2022-12-20 |
2024-06-27 |
Genentech, Inc. |
Methods of treating pancreatic cancer with a pd-1 axis binding antagonist and an rna vaccine
|
WO2024151811A1
(en)
|
2023-01-11 |
2024-07-18 |
Modernatx, Inc. |
Personalized cancer vaccines
|
WO2024153324A1
(en)
|
2023-01-18 |
2024-07-25 |
BioNTech SE |
Rna formulations for pharmaceutical use
|
WO2024159172A1
(en)
|
2023-01-27 |
2024-08-02 |
Senda Biosciences, Inc. |
A modified lipid composition and uses thereof
|
WO2024163465A1
(en)
|
2023-01-30 |
2024-08-08 |
Modernatx, Inc. |
Epstein-barr virus mrna vaccines
|